Biodesix Announces Second Quarter 2021 Results and Highlights

Rhea-AI Summary

Biodesix, Inc. (BDSX) reported a strong second quarter for 2021, highlighting 180% growth in total revenue to $11.9 million, driven by a 109% increase in core lung diagnostic revenue. The company anticipates ongoing growth supported by its expanding sales force and emerging from the pandemic. Notably, COVID-19 testing revenue surged 345%, although a sequential decline was noted as vaccinations progressed. Despite a 38% rise in net loss to $11.4 million, Biodesix maintains a robust cash position of $56.3 million as of June 30, 2021.

Positive

• Total revenue grew by 180% year over year to $11.9 million.
• Core lung diagnostic revenue increased by 109% year over year to $4.8 million.
• COVID-19 testing revenue surged 345% to $6.1 million.
• Gross profit rose 103% to $4.8 million.
• Maintained strong liquidity with cash and cash equivalents of $56.3 million.

Negative

• Net loss increased by 38% to $11.4 million.
• Gross margin declined from 56% to 40%, primarily due to lower margins from COVID-19 testing.
• Operating expenses increased 93% to $15.4 million, reflecting substantial investments in sales expansion.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the second quarter ended June 30, 2021 and provided a corporate update.

“It was a productive quarter with 180% year over year growth in total revenue. Our first four blood-based tests which make up our core lung diagnostic testing, grew 109% year over year and 20% over the prior quarter,” said Scott Hutton, CEO of Biodesix. “We expect growth in core lung diagnostic testing to continue through 2021 driven by the U.S.’s emergence from the pandemic, productivity from our growing salesforce, and our efforts to build on the body of evidence supporting the use of our tests. Beyond our currently marketed products, we also continue to develop our Diagnostic Cortex® Artificial Intelligence (AI) platform and expand our pipeline of products capable of providing broad lung diagnostics to address patients' needs over the course of their disease. The launch of our 72-hour liquid NGS test is now projected for the first quarter of 2022 and will supplement our 36-hour VeriStrat and GeneStrat tests. With this accelerated launch and multiple studies underway for our Risk of Recurrence (ROR) and Primary Immune Response (PIR) tests as well as our ALTITUDE, BEACON, INSIGHT, and ORACLE prospective studies actively enrolling or following patients, we look forward to a productive and exciting second half of the year.”

Second Quarter 2021 Financial Results

For the three-month period ended June 30, 2021, as compared to the same period of 2020 (where applicable):

• Total revenue of $11.9 million, an increase of 180%;
  
  
• Core lung diagnostic revenue of $4.8 million, an increase of 109%;
  • Continued sequential recovery from initial rapid uptake of COVID-19 immunizations.
  • Growth driven primarily by Nodify XL2® and Nodify CDT®.
  • Nodify XL2 growth triggered the previously disclosed milestone resulting in a $37 million obligation payable by us over six quarterly installments of approximately $4.6 million beginning January 2022 and a final payment of approximately $9.3 million in July 2023.
    

• COVID-19 testing revenue of $6.1 million, an increase of 345%;
  • Sequential quarter over quarter decline commensurate with our prior commentary as US immunizations accelerated in second quarter.
    

• Services revenue of $1.0 million, an increase of 76%;
  • Clinical trial services showed improvement and we expect further recovery in clinical trial enrollments in second half of 2021.
    
    
• Gross profit of $4.8 million, an increase of 103%, and gross margin percentage of 40% as compared to 56% representing a decline primarily attributable to the lower gross margin COVID-19 testing;
  
  
• Operating expenses (excluding direct costs and expenses) of $15.4 million, which includes an investment in the planned expansion of our sales force, increased 93% over second quarter 2020;
  • On track to double size of lung focused direct and dedicated sales force in 2021.
  • Non-cash stock compensation expense of $0.5 million as compared to $0.1 million.
  • Non-cash expense for change in fair value of contingent consideration of $0.6 million as compared to a gain of $1.0 million.
    
    
• Net loss of $11.4 million, an increase of 38% over second quarter of 2020; and
  
  
• Maintained fiscal discipline and strong liquidity with cash and cash equivalents of $56.3 million as of June 30, 2021 and expect to qualify for PPP loan forgiveness of $3.1 million later in 2021.

For a full list of Biodesix’s press releases and webinars, please visit Biodesix.com.

Conference call and webcast information

Management will host an investor conference call and webcast today, August 10, 2021 at 4:30 p.m. Eastern Time.

Investor dial-in (domestic): 833-665-0678
Investor dial-in (international): 929-517-0173
Conference ID: 6519549
Webcast: https://edge.media-server.com/mmc/p/2hp2grhc

An archived replay of the webcast will be available on the Company’s website for a period of 90 days.

About Biodesix

Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer seven non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass ™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 36 hours, expediting time to treatment. The blood-based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT™ tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, visit biodesix.com.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 16, 2021 or subsequent quarterly reports on Form 10-Q during 2021, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Biodesix, Inc. Condensed Balance Sheets (unaudited) (in thousands)
		June 30, 2021				December 31, 2020
Assets
Current assets
Cash and cash equivalents		$	56,349			$	62,126
Accounts receivable, net of allowance for doubtful accounts of $168 and $180			5,281				15,304
Other current assets			6,820				8,710
Total current assets			68,450				86,140
Non-current assets
Property and equipment, net			3,378				3,178
Intangible assets, net			12,400				13,260
Other long-term assets			2,545				3,461
Goodwill			15,031				15,031
Total non-current assets			33,354				34,930
Total assets		$	101,804			$	121,070
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable		$	1,160			$	8,964
Accrued liabilities			6,198				7,789
Deferred revenue			2,182				3,532
Current portion of contingent consideration			8,626				—
Current portion of notes payable			3,106				11,840
Total current liabilities			21,272				32,125
Non-current liabilities
Long-term notes payable, net of current portion			29,955				15,926
Contingent consideration			23,217				29,932
Other long-term liabilities			1,587				1,921
Total non-current liabilities			54,759				47,779
Total liabilities			76,031				79,904
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 (2021 and 2020) shares issued and outstanding			—				—
Common stock, $0.001 par value, 200,000,000 shares authorized; 26,948,879 (2021) and 26,561,504 (2020) shares issued and outstanding			27				27
Additional paid-in capital			302,923				299,953
Accumulated deficit			(277,177	)			(258,814	)
Total stockholders' equity			25,773				41,166
Total liabilities and stockholders' equity		$	101,804			$	121,070

Biodesix, Inc. Condensed Statements of Operations (unaudited) (in thousands, except share data)
		Three Months Ended June 30,								Six Months Ended June 30,
		2021				2020				2021				2020
Revenues
COVID-19		$	6,064			$	1,363			$	29,296			$	1,363
Lung diagnostic			4,774				2,280				8,737				5,883
Diagnostic testing revenue			10,838				3,643				38,033				7,246
Biopharma services			1,047				596				2,718				2,089
Total revenues			11,885				4,239				40,751				9,335
Direct costs and expenses			7,085				1,874				25,303				3,455
Research and development			3,323				2,107				6,644				5,007
Sales, marketing, general and administrative			11,425				6,834				23,352				14,914
Change in fair value of contingent consideration			639				(957	)			1,622				—
Total operating expenses			22,472				9,858				56,921				23,376
Loss from operations			(10,587	)			(5,619	)			(16,170	)			(14,041	)
Other income (expense):
Interest expense			(815	)			(2,784	)			(1,466	)			(4,241	)
Change in fair value of warrant liability			—				4				—				55
Loss on debt extinguishment			—				—				(728	)			—
Other income, net			—				133				1				256
Total other expense			(815	)			(2,647	)			(2,193	)			(3,930	)
Net loss		$	(11,402	)		$	(8,266	)		$	(18,363	)		$	(17,971	)
Net loss per share, basic and diluted		$	(0.41	)		$	(30.06	)		$	(0.68	)		$	(68.85	)
Weighted-average shares outstanding, basic and diluted			27,730				275				27,020				261

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005952/en/

FAQ

What were Biodesix's total revenues for Q2 2021?

Biodesix reported total revenues of $11.9 million for Q2 2021, reflecting a 180% year-over-year growth.

What is the growth rate of core lung diagnostic revenue for Biodesix?

Core lung diagnostic revenue increased by 109% year over year to $4.8 million.

How much cash did Biodesix have at the end of Q2 2021?

As of June 30, 2021, Biodesix maintained cash and cash equivalents of $56.3 million.

What was the net loss reported by Biodesix for the second quarter of 2021?

Biodesix reported a net loss of $11.4 million for Q2 2021, a 38% increase compared to the previous year.

How did COVID-19 testing revenue perform in Q2 2021 for Biodesix?

COVID-19 testing revenue for Biodesix surged 345% to $6.1 million, although a sequential decline was noted.